🛡️ immunology

Long-term rapamycin treatment suppresses IL-17-producing gamma delta T cells and blunts neuroinflammation in aging

Long-term low-dose rapamycin treatment selectively suppresses the age-associated expansion of IL-17-producing gamma delta T cells and mitigates related neuroinflammation without significantly altering overall innate or adaptive immune cell populations.

Original authors: Torrent, C., Gagliardi, C., Fülle, N., Antignano, I., Bernis, M. E., Stork, M., Bano, D., Capasso, M., Keane, L.

Published 2026-02-06

📖 3 min read☕ Coffee break read

CC BY 4.0

Original authors: Torrent, C., Gagliardi, C., Fülle, N., Antignano, I., Bernis, M. E., Stork, M., Bano, D., Capasso, M., Keane, L.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

Imagine your body as a bustling city that, over many years, starts to accumulate a bit of "wear and tear." As the city ages, its security forces (the immune system) sometimes get a little too jittery, causing low-level, constant noise and friction known as "inflammaging." This background noise can eventually lead to trouble in sensitive areas, like the brain's control center.

Scientists have long known about a drug called rapamycin. Think of rapamycin as a "traffic regulator" for the cell's internal engine (the mTOR pathway). In transplant patients, it's used to calm down an overactive immune system so it doesn't attack a new organ. Because it slows down this engine, it has also been shown to help various animals live longer and stay healthier. However, people worry: if we use this drug to fight aging, will it make our immune system too weak, leaving us defenseless against real threats?

To answer this, researchers gave aging mice a small, steady dose of rapamycin in their food for a long time and watched what happened to their immune "city."

Here is what they found:

The General Police Force Stayed the Same: The drug didn't cause a mass exodus of the city's standard security teams. The usual suspects—innate and adaptive immune cells, and even the brain's own resident guards (microglia)—remained largely unchanged. The city wasn't left defenseless.
A Specific Group Was Calmed Down: However, the researchers noticed one specific group of troublemakers: IL-17-producing gamma delta T cells. Imagine these as a small, specialized squad of firefighters that, as the city ages, starts to multiply uncontrollably and set off false alarms. The rapamycin treatment successfully stopped this specific squad from over-growing, especially in the body's "storage areas" (the peritoneal cavity).
The Brain Stayed Quieter: When the researchers later gave the mice a simulated "emergency" (a bacterial trigger called LPS) to see how they reacted, the treated mice responded much better. Because that specific squad of T-cells was kept in check, the levels of inflammatory signals (IL-17) in the blood stayed low. Consequently, the brain's guards (microglia) didn't get as worked up or aggressive as they usually do in aging bodies.

The Bottom Line:
This study suggests that taking a low dose of rapamycin over a long time is like a targeted tune-up rather than a total shutdown. It doesn't strip the body of its general defenses, but it specifically stops one particular type of aging immune cell from expanding. By keeping that specific group in check, the drug helps prevent the brain from getting caught up in unnecessary inflammation when the body faces stress, all without causing major systemic changes to the rest of the immune system.

Technical Summary: Long-term Rapamycin Treatment Suppresses IL-17-Producing Gamma Delta T Cells and Blunts Neuroinflammation in Aging

Problem Statement
Aging is characterized by the gradual accumulation of structural and functional changes, notably immune remodeling and a progressive rise in basal inflammation known as "inflammaging." The mechanistic target of rapamycin (mTOR) pathway serves as a central driver in aging-related pathologies, including cancer, chronic inflammation, and neurodegeneration. While pharmacological inhibition of mTOR via rapamycin has been linked to reduced age-related morbidity and increased lifespan across species, its clinical translation as an anti-aging intervention faces significant hurdles. Specifically, rapamycin is a well-established immunosuppressant used in transplant medicine, raising concerns that its long-term use might compromise immune competence or induce adverse systemic immune effects. The core problem addressed is whether prolonged, low-dose rapamycin can mitigate age-related inflammation and neuroinflammation without causing broad, detrimental suppression of the immune system.

Methodology
The study evaluated the impact of prolonged, low-dose dietary rapamycin treatment on the aging immune system. The experimental design focused on assessing:

Systemic Immune Profiling: Examination of innate and adaptive immune cell populations to detect broad immunosuppressive effects.
Tissue-Specific Analysis: Investigation of brain-resident microglia and peripheral immune compartments, specifically the peritoneal cavity.
Inflammatory Challenge: Subjects were subjected to a peripheral inflammatory challenge using lipopolysaccharide (LPS) to test the system's response to acute inflammation.
Phenotypic Correlation: Measurement of circulating IL-17 levels and the inflammatory phenotype of microglia following the LPS challenge to establish correlations between peripheral immune changes and central nervous system responses.

Key Contributions and Results
The study provides a nuanced characterization of how low-dose rapamycin interacts with the aging immune landscape:

Preservation of General Immunity: Long-term treatment did not significantly alter the composition of major innate or adaptive immune cell populations, nor did it affect brain-resident microglia under baseline conditions. This suggests that the treatment does not induce broad, non-specific immunosuppression.
Selective Suppression of $\gamma\delta$ T Cells: The treatment specifically attenuated the age-associated accumulation of IL-17-producing gamma delta ( $\gamma\delta$ ) T cells. This suppression was particularly pronounced in the peritoneal cavity.
Attenuation of Neuroinflammation: Following a peripheral LPS challenge, animals treated with rapamycin exhibited significantly reduced circulating IL-17 levels. Crucially, this reduction correlated with a dampened inflammatory phenotype in microglia, indicating a protective effect against systemic inflammation-induced neuroinflammation.

Significance and Claims
The paper concludes that prolonged low-dose rapamycin exposure exerts minor systemic immune changes rather than global immunosuppression. Its primary significance lies in demonstrating that rapamycin can selectively limit the expansion of age-related IL-17-producing $\gamma\delta$ T cells. By targeting this specific cell population, the treatment effectively blunts the neuroinflammation associated with systemic inflammation. These findings support the potential of low-dose rapamycin as an anti-aging intervention that mitigates specific drivers of inflammaging and neuroinflammation while maintaining overall immune integrity.

Technical Summary: Long-term Rapamycin Treatment Suppresses IL-17-Producing Gamma Delta T Cells and Blunts Neuroinflammation in Aging

More like this